Jeil Pharm (002620) — Capital Reinvestment Ratio
Latest as of March 2026:
3.85x
Jeil Pharm (002620) has a Capital Reinvestment Ratio of 3.85x as of March 2026, meaning it reinvests 4% of its operating cash flow (₩447.08 Million) in capital expenditures (₩1.72 Billion). See 002620 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
3.85x
Capex / Operating Cash Flow
Operating Cash Flow
₩447.08 Million
KRW
Capital Expenditures
₩1.72 Billion
KRW
Data as of
Mar 2026
Most recent filing
Jeil Pharm Capital Reinvestment Ratio (2011–2025)
This chart tracks Jeil Pharm's Capital Reinvestment Ratio across 8 annual periods.
Annual Capital Reinvestment Ratio for Jeil Pharm (2011–2025)
Year-by-year Capital Reinvestment Ratio for Jeil Pharm from 2011 to 2025. For live market cap and broader valuation context, see 002620 company net worth.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 23.90x | ₩390.26 Million | ₩9.33 Billion | ▲ +1481.9% |
| 2024 | 1.51x | ₩4.54 Billion | ₩6.86 Billion | ▼ -14.5% |
| 2021 | 1.77x | ₩13.40 Billion | ₩23.69 Billion | ▲ +18.3% |
| 2019 | 1.49x | ₩25.22 Billion | ₩37.69 Billion | ▲ +201.2% |
| 2017 | 0.50x | ₩5.92 Billion | ₩2.94 Billion | ▼ -81.4% |
| 2016 | 2.67x | ₩11.36 Billion | ₩30.33 Billion | ▲ +8.7% |
| 2015 | 2.46x | ₩2.74 Billion | ₩6.74 Billion | ▲ +159.2% |
| 2011 | 0.95x | ₩23.63 Billion | ₩22.40 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow